Comparative Pharmacology
Head-to-head clinical analysis: PEMAZYRE versus SUNITINIB MALATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEMAZYRE versus SUNITINIB MALATE.
PEMAZYRE vs SUNITINIB MALATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4; binds to and inhibits FGFR kinase activity, leading to decreased tumor cell proliferation and angiogenesis.
Sunitinib is a multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase 3 (FLT3), colony-stimulating factor receptor type 1 (CSF-1R), and glial cell line-derived neurotrophic factor receptor (RET). It exerts antiangiogenic and antitumor activity by blocking signaling pathways involved in tumor growth and angiogenesis.
13.5 mg orally once daily continuously until disease progression or unacceptable toxicity.
50 mg orally once daily for 4 weeks, followed by 2 weeks off (4/2 schedule). Alternatively, 37.5 mg orally once daily on a continuous daily dosing schedule for gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor failure.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 14–32 h), supporting once-daily dosing with steady-state reached within 8 days.
40-60 hours for sunitinib; 80-110 hours for active metabolite SU12662. Clinical context: supports once-daily dosing with 2 weeks on/1 week off schedule.
Primarily hepatobiliary excretion: 72% of the dose recovered in feces (mainly as unchanged drug and metabolites); renal excretion accounts for approximately 17% (less than 1% unchanged).
Fecal (61%), renal (16%) as unchanged drug and metabolites.
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor